Recent DTIL News
- Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting • Business Wire • 05/14/2026 11:01:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/05/2026 11:20:04 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 11:19:27 AM
- Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update • Business Wire • 05/05/2026 11:01:00 AM
- Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026 • Business Wire • 04/30/2026 11:01:00 AM
- Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study • Business Wire • 04/29/2026 11:01:00 AM
- Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting • Business Wire • 04/28/2026 11:01:00 AM
- Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/24/2026 11:01:00 AM
- Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026 • Business Wire • 04/22/2026 11:01:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/15/2026 01:46:19 PM
- Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries • Business Wire • 04/15/2026 11:01:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/08/2026 11:01:42 AM
- Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference • Business Wire • 04/08/2026 11:01:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/08/2026 11:00:28 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/27/2026 08:05:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 12:31:07 PM
- Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update • Business Wire • 03/12/2026 11:00:00 AM
- Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program • Business Wire • 03/11/2026 11:01:00 AM
- Precision BioSciences reports encouraging muscle improvements in preclinical DMD gene therapy study • IH Market News • 03/10/2026 11:17:45 AM
- Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026 • Business Wire • 03/10/2026 11:01:00 AM
- Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 • Business Wire • 03/09/2026 08:15:00 PM
- Precision BioSciences shares jump after FDA grants Fast Track status to Duchenne therapy • IH Market News • 03/09/2026 02:09:07 PM
- Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event • Business Wire • 03/09/2026 11:01:00 AM
- Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis • Business Wire • 03/02/2026 12:01:00 PM
